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We reviewed our experience with vagus nerve stimulation (VNS) in 165 patients with medically refractory epilepsy (138 partial
epilepsy (PE), 13 symptomatic generalised epilepsy (SGE), 14 idiopathic generalised epilepsy (IGE)). Average duration of VNS
therapy was 21.6 months. A 50% or greater reduction in seizure frequency was achieved in 47.1% of the PE group, 46.1% of
the SGE group, and 57.1% of the IGE group. A 50% or greater reduction in seizure frequency and reduced antiepileptic drug
(AED) regimen were achieved in: PE (9.4%), SGE (7.7%), and IGE (35.7%). These preliminary results suggest that VNS is an
effective therapy for some patients with medically refractory IGE.
© 2003 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved.
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INTRODUCTION
Vagus nerve stimulation (VNS) is a palliative treat-
ment for medically refractory epilepsy in patients over
12 years of age with partial onset seizures1. Off-label
use of VNS has included children ages nine months
and older2, as well as idiopathic and symptomatic gen-
eralised epilepsies (SGEs)3. Controlled data are not
available for these off-label uses.
Labar et al. found that VNS was effective in a
study of 24 patients, aged 4 years and older, with
medication-resistant generalised epilepsy4. Short-term
efficacy during a three-month period was compared
to a one-month baseline period with stable antiepilep-
tic drug (AED) therapy. Median reduction in seizure
frequency was 46%, suggesting that VNS was an ef-
fective treatment for medication resistant generalised
epilepsy.
We studied VNS treatment for a longer period
in 14 patients with idiopathic generalised epilepsy
(IGE) and compared them to results in 151 pa-
tients with partial epilepsy (PE) and SGE, examining
seizure control and changes in AED therapy after
implantation.
METHODS
We evaluated the results of VNS in patients implanted
between 1994 and 2000 at the NYU Comprehensive
Epilepsy Center. Data was gathered via systematic
review of medical records. All patients were diag-
nosed with medically refractory epilepsy, and were
implanted with a VNS. A baseline of three months
was established, and patients were followed for a min-
imum of three months. We evaluated the reduction in
seizure frequency in this cohort, as well as change in
AED regimen after VNS implantation. Seizure type
and epilepsy syndrome were defined using the Inter-
national League Against Epilepsy criteria5.
To identify patients with an excellent response to
VNS therapy, we used stricter criteria for ‘responders’.
Responders were defined as having a 50% or greater
reduction in seizure frequency and a concurrent re-
duction in medication regimen. Non-responders were
defined as meeting at least one of these criteria:
(1) less than 50% reduction in seizure frequency; or
(2) no change or increase in AED regimen. Reduc-
tion in medication regimen was defined as any of the
following: (1) decrease in dosage of AED regimen;
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(2) decrease in number of AEDs; (3) both; or (4)
termination of all AEDs.
RESULTS
VNS were implanted in 165 patients for whom ade-
quate follow-up was available. Fourteen patients had
IGE. Of the remaining 151 patients, 138 had PE and
13 had SGE. Eighty-eight patients (53%) were male;
77 (47%) were female. For the IGE group, 7 (50%)
were male. Mean age at the time of study was 27.3
years (range, 6–73 years). For the IGE group, the
mean age at time of study was also 27.3 years (range,
13–45 years). Mean age of seizure onset was 8.5 years
(range, 0–56 years). For the IGE group, the mean age
of seizure onset was 8.2 years (range, 0.5–23 years).
Among the 151 patients with PE and SGE, the cause
was unknown in 77. In these two groups, perinatal
anoxia or other early life vascular insults (n = 19),
head injury (n = 14), encephalitis (n = 12), be-
nign brain tumor without evidence of growth during
the study period (n = 8), hydrocephalus (n = 7),
and tuberous sclerosis (n = 4) were the most com-
monly identified sources. No etiology for epilepsy was
present in the patients with IGE. MRI results for the
overall group were negative in 78 (47.2%), abnormal
in 74 (44.8%), and not available in 13 (7.8%). Full
scale IQ (FSIQ) for the overall group revealed severe
developmental delay in 27 (16.4%) and mental retar-
dation (MR) in 32 (19.4%). FSIQ results were not
available for 16 patients. Of the remaining 90 patients,
FSIQ mean was 84.5.
Average duration of VNS therapy in the overall
group was 21.6 months: PE group (20.7 months),
SGE group (27.5 months), and IGE group (16.5
months).
Table 1: Results of VNS treatment.
Partial Symptomatic generalised Primary generalised
(n = 138) (n = 13) (n = 14)
Average age 28.1 18.7 27.3
Sex 72 (52%) male 4 (30.8%) male 7 (50%) male
66 (48%) female 9 (69.2%) female 7 (50%) female
Number of years w/epilepsy 19.3 16.4 17.8
VNS treatment duration (months) 20.7 27.5 16.5
Mean VNS (A) 1.3 1.15 1.11
Mean % reduction in seizure frequency (all) 58.9 57.3 72.9
Percent of patients with decrease in AEDs 20.3 (28) 23.1 (3) 35.7 (5)
Percent responders with >50% reduction seizure
frequency and decrease in AEDs
9.4 (13) 7.7 (1) 35.7 (5)
Percent responders with <50% reduction in seizures
or no change
41.3 (57) 46.2 (6) 35.7 (5)
Percent responders with increased seizure frequency 11.6 (16) 7.7 (1) 7.1 (1)
Percent responders with >50% reduction in seizure
frequency but non-responders (no decrease in AEDs)
37.7 (52) 38.5 (5) 21.4 (3)
Table 1 summarises the changes in seizure fre-
quency after VNS for different patient groups. In the
PE group, 65 (47.1%) had a 50% or greater reduction
in seizure frequency, 57 (41.3%) had less than 50%
reduction in seizure frequency, and 16 (11.6%) had
an increase in seizure frequency. In the SGE group,
six (46.1%) had a 50% or greater reduction in seizure
frequency, six (46.1%) had less than 50% reduction
in seizure frequency, and one (7.7%) had an increase
in seizure frequency. In the IGE group, eight (57.1%)
had a 50% or greater reduction in seizure frequency,
five (35.7%) had less than 50% reduction in seizure
frequency, and one (7.1%) had an increase in seizure
frequency (Table 1).
Fourteen patients with IGE were compared to 151
patients with PE and SGE. Of the 14 patients with IGE,
5 (35.7%) were responders as we define them. One
(7.7%) of 13 patients with SGE was a responder. Thir-
teen (9.4%) of 138 patients with PE were responders.
Of the IGE responders, MRI was negative in two,
abnormal in one, and not available in two. The SGE
responder had an abnormal MRI. Of the PE respon-
ders, MRI was negative in seven, abnormal in five, and
not available in one. Of the IGE responders, one had
severe developmental delay, one was MR, and three
had FSIQ >70. The SGE responder did not have a
FSIQ available. Of the PE responders, one had severe
developmental delay, three were MR, and eight had
FSIQ greater than 70. One PE responder did not have
FSIQ available.
All five responders in the IGE group had reductions
in the dosage of their AED regimens. The responder
in the SGE group also had a reduction in AED reg-
imen dosage. Of the PE group responders, eight had
a reduction in AED regimen dosage, four had both a
reduction in dosage and number of medications, and
one responder had all AEDs stopped.
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DISCUSSION
Our findings suggest that VNS is an effective therapy
for some patients with medication resistant IGE. These
uncontrolled, retrospective observations suggest that
patients with refractory IGE may enjoy both a greater
reduction in seizure and medication burden with the
VNS than those with refractory PE. We did not specif-
ically look at quality of life issues with regard to
decreased AED regimen. Advantages to patients and
their families likely include decreased financial burden
and psychological burden. Furthermore, the medica-
tion burden could possibly be further decreased with
increased duration of VNS treatment.
Our findings support and expand the prior findings
of Labar’s group4. We also found that within the group
of patients with generalised epilepsies, those with id-
iopathic disorders may have a better response to VNS
than those with symptomatic forms. We studied pa-
tients for a longer interval after VNS implantation
than in Labar et al.’s study (mean 21.6 months vs.
3 months)4. Our observations suggest that the du-
ration of VNS efficacy in generalised epilepsies is
sustained.
Our criteria for responders were stricter than most
prior studies, requiring a reduction in medication num-
ber or dosage, as well as a reduction in seizure fre-
quency. Specifically, we were interested in the subset
with IGE. Individuals with IGE had a larger propor-
tion of responders than groups with individuals with
PE or SGE. Additional prospective studies are needed
to better define the role of VNS in medically refrac-
tory IGE and determine if specific IGE may respond
better to this therapeutic modality.
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